Spondyloarthropathies News

The FDA has issued a warning letter to MediNatura Inc., ordering the company to cease illegal marketing of unapproved injectable homeopathic products that claim to treat “inflammatory and degenerative conditions of the musculoskeletal system” and relieve pain, swelling and joint stiffness.

Treatment with bimekizumab over 48 weeks resulted in rapid, sustained improvements in patient-reported outcomes, sleep and quality of life among those with ankylosing spondylitis, according to data presented at the EULAR 2020 E-Congress.

Lifestyle approaches, including physical activity and smoking cessation, should complement medical therapy in patients with rheumatic and musculoskeletal diseases, according to data presented at the EULAR 2020 E-Congress.

A EULAR task force has published the first evidence-based recommendations to guide clinicians administering intra-articular injections in patients with arthropathies, according to data presented at the EULAR 2020 E-Congress.

Certolizumab pegol may be safely reduced in patients across the axial spondyloarthritis spectrum who have achieved sustained disease remission on a full dose of the drug, according to data presented at the EULAR 2020 E-Congress.

Patients treated with biologic therapy for inflammatory diseases may not have a higher risk for developing melanoma, a systematic review and meta-analysis found.

Patients with early axial spondyloarthritis who achieved sustained remission at 48 weeks can reduce their maintenance dose of certolizumab pegol, although complete discontinuation should be avoided due to a high risk for flares, according to data published in the Annals of the Rheumatic Diseases.

The FDA has expanded the approval of ixekizumab injection 80 mg/mL to include treatment of active nonradiographic axial spondyloarthritis in patients with objective signs of inflammation.

The COVID-19 pandemic, in places like Detroit, with a large working-class population, can highlight the gap between the rich and the poor. It can demonstrate how political unrest can impact the response to a critical situation. Moreover, it can show how health care workers can face both personal and professional challenges in managing an outbreak of this magnitude.

As a general rule, rheumatologists are comfortable with ambiguous diagnoses, given that so many of the conditions they manage are marked by a wide spectrum of presentations and manifestations. A prime example is axial spondyloarthritis, which is divided into two categories: radiographic axial spondyloarthritis — also called ankylosing spondylitis — and nonradiographic axial spondyloarthritis. Discussion surrounding the nonradiographic form of this disease has been known to prompt the almost preposterous fundamental question: Is it even a thing?